Shared on04 Sep 25
Given that both the consensus revenue growth forecast and future P/E remained steady, there has been no material change in analyst sentiment, resulting in the consensus price target for Aurobindo Pharma remaining unchanged at ₹1293. What's in the News Aurobindo Pharma has emerged as the frontrunner to acquire Prague-based generic drugmaker Zentiva Group for $5–5.5 billion from Advent International, which would be the largest-ever acquisition by an Indian pharma company; the acquisition would significantly boost Aurobindo’s footprint in the Eastern European market, especially in Czech Republic, Romania, and Slovakia (Key Developments).
Shared on23 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Decreased 0.45%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25Fair value Increased 12%
AnalystConsensusTarget has decreased revenue growth from 8.8% to 7.3% and increased future PE multiple from 21.8x to 24.5x.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25Fair value Increased 8.62%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on12 Mar 25Fair value Decreased 3.05%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.